Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 0.83% | 145.13 | 0.7% | $900.66m | |
| PFE | Pfizer Inc. | 1.03% | 37.46 | 0.9% | $772.03m | |
| MRK | Merck & Co., Inc. | 1.45% | 79.20 | 0.7% | $634.61m | |
| BMY | Bristol-Myers Squibb Co. | 1.22% | 60.76 | 1.0% | $630.06m | |
| ABBV | AbbVie, Inc. | 1.70% | 84.30 | 1.9% | $601.86m | |
| LLY | Eli Lilly & Co. | 0.20% | 141.59 | 1.1% | $484.74m | |
| AZN | AstraZeneca Plc | 0.76% | 51.96 | 1.2% | $203.71m | |
| NVS | Novartis AG | 0.37% | 84.45 | 0.2% | $142.55m | |
| GSK | GlaxoSmithKline Plc | -0.74% | 35.09 | 0.2% | $137.88m | |
| NVO | Novo Nordisk A/S | 0.06% | 70.89 | 0.1% | $69.98m | |
| RGEN | Repligen Corp. | 2.77% | 176.51 | 7.1% | $64.16m | |
| RPRX | Royalty Pharma Plc | 0.54% | 39.21 | 0.2% | $64.00m | |
| SNY | Sanofi | -0.49% | 48.93 | 0.2% | $49.73m | |
| AMAG | AMAG Pharmaceuticals, Inc. | 0.22% | 13.66 | 22.1% | $45.13m | |
| PRAX | Praxis Precision Medicines, Inc. | 6.95% | 32.00 | 0.0% | $43.27m |
Company Profile
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.